Lisa Rivera
Psychiatric/Mental Health · Suffolk, VANPI 1225200066
Payments from drug & device makers
Across 207 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$855
- Teva Pharmaceuticals USA, Inc.$678
- AbbVie$540
- Alkermes, Inc.$483
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$446
- E.r. Squibb & Sons, L.L.C.$344
- plus $718 from 6 others
What the payments were for
- Food & beverage$3,89696%
- Education$1674%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 28 | $855 |
| Teva Pharmaceuticals USA, Inc. | 33 | $678 |
| AbbVie | 36 | $540 |
| Alkermes, Inc. | 27 | $483 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $446 |
| E.r. Squibb & Sons, L.L.C. | 15 | $344 |
| Otsuka America Pharmaceutical, Inc. | 17 | $330 |
| Neurocrine Biosciences, Inc. | 10 | $205 |
| Lundbeck LLC | 4 | $63 |
| Vanda Pharmaceuticals Inc. | 3 | $54 |
| Indivior Inc. | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$134
- AUSTEDO$111
How this compares
$4,063 in reported general payments places this provider in the 85th percentile of 1,003 psychiatric/mental health providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 23 | $186,714 |
| AustedoDeutetrabenazine | 22 | $115,197 |
| Invega SustennaPaliperidone Palmitate | 26 | $74,776 |
| Abilify MaintenaAripiprazole | 24 | $68,897 |
| Olanzapine | 112 | $7,693 |
| Aripiprazole | 58 | $7,576 |
| Asenapine Maleate | 20 | $5,759 |
| Clozapine | 64 | $4,816 |
| Divalproex Sodium | 70 | $3,834 |
| Divalproex Sodium ErDivalproex Sodium | 53 | $3,177 |
| Oxcarbazepine | 43 | $2,219 |
| Quetiapine Fumarate | 103 | $2,165 |
| Methylphenidate Hcl Er (Cd)Methylphenidate Hcl | 12 | $2,146 |
| Benztropine Mesylate | 157 | $2,013 |
| Trazodone Hcl | 71 | $1,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $855 | $261,48949 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $678 | $115,19722 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $330 | $68,89724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Suffolk
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Juliana FroschAmherst$36K
- Derick ReedyNickelsville$23K
- Pamela RuppelRoanoke$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.